Where Parkinson's disease treatment is heading
Parkinson's disease · Updated Nov 12, 2026
Medicines and devices control movement symptoms for years, and a new once-daily pill arrived in 2026. Nothing yet slows the disease, and three high-profile attempts failed in 2025 and 2026. The next tests are an antibody and cell transplants.
- 1,083studies open or running
- 24of them in phase 3
- 9,637papers published this year
- 140NIH-funded projects
-
Now
Nov 2026
New once-daily pill approvedHappened 1.7 vs 0.6 extra good hours a day
Tavapadon works on different dopamine receptors from older drugs and can be taken with or without levodopa.
1.7 vs 0.6: extra hours a day of good movement, tavapadon vs placebo.
Three attempts to slow it failedHappened 5.7 vs 4.5 points worse, no benefit
A diabetes drug and two drugs aimed at genetic pathways did not slow the disease in trials reported in 2025 and 2026.
5.7 vs 4.5: points of worsening, exenatide vs placebo.
Stem cell transplants look safeHappened 8 people, no serious harm
The first people given lab-grown dopamine cells had no serious harm from them.
8: people treated, with no serious harm from the cells.
-
6 months
by May 2027
CVN424 phase 3 resultPossible
A non-dopamine pill for people whose levodopa wears off. The 330-person trial is fully enrolled and passed its completion date in August 2026.
Exercise trial reportsPossible
SPARX3, an NIH-funded phase 3 trial of high-intensity treadmill exercise in early Parkinson's, reached the end of its funding period in August 2026.
-
12 months
by Nov 2027
BHV-8000 trial finishesPossible
A pill aimed at inflammation in the brain, tested in 550 people with early disease.
LRRK2 drug in gene carriersLong shot
After the failure in people without the gene variant, trials in people who carry it are the remaining test of this approach.
-
3 years
by late 2029
First sham-controlled cell transplant resultPossible 8 people treated safely so far
Bemdaneprocel against sham surgery in 102 people finishes in late 2028. It will show whether the cells improve movement.
8: people treated in the earlier Swedish study, with no serious harm from the cells.
Prasinezumab phase 3 verdictPossible
A 900-person trial of the alpha-synuclein antibody finishes in mid-2029.
Ambroxol resultPossible
A cough medicine that boosts a cell-cleaning enzyme, tested for two years in 330 people.
-
5 years
by late 2031
Several repurposed drugs tested at oncePossible
A 1,200-person UK platform trial tests existing medicines side by side against one placebo group, and can add more.
A drug that slows Parkinson'sLong shot
Approval of a first treatment that changes the course of the disease, from the antibody, ambroxol or a platform-trial drug.
Gene therapy to protect dopamine cellsLong shot
A one-time gene therapy delivering a growth factor (GDNF) to the brain is in a surgery-controlled trial.
The research paths
Better symptom control
1.7 vs 0.6 extra good hours a dayDetails and 2 trialsHide
New pills and delivery methods aim for steadier control with fewer involuntary movements.
WatchCVN424, a non-dopamine pill.
Replacing lost dopamine cells
8 people, no serious harmDetails and 2 trialsHide
Lab-grown dopamine cells, or a gene therapy to protect the remaining ones, placed in the brain by surgery.
WatchThe first trial with sham surgery as a comparison.
Clearing alpha-synuclein
Details and 1 trialsHide
Alpha-synuclein is the protein that clumps in Parkinson's. The antibody against it missed its goal in mid-stage testing but showed enough to justify a larger trial.
WatchWhether the phase 3 result is clear, not a subgroup signal.
Drugs matched to genes
Details and 2 trialsHide
Drugs aimed at the LRRK2 and GBA pathways failed in broad groups in 2026. Trials continue in people who carry the matching gene variants.
WatchResults in gene-variant carriers.
Repurposed and new protective drugs
5.7 vs 4.5 points worse, no benefitDetails and 3 trialsHide
Existing medicines tested for a protective effect. Exenatide failed. A platform trial now tests several at once.
WatchThe platform trial's first arms.
Borrowed from other conditions
From Diabetes
Exenatide
5.7 vs 4.5 points worse, no benefit
Failed in phase 3
A GLP-1 injection. It did not slow Parkinson's in a two-year trial.
From Cough medicine
Ambroxol
Phase 3
Raises the activity of an enzyme that helps cells clear waste, which is low in some people with Parkinson's.
From Blood pressure treatment
Telmisartan
Phase 3 platform
One of the existing medicines in the UK platform trial.
From Alzheimer's research
Buntanetap
Phase 3
A pill meant to lower production of several clumping proteins, tested in both diseases.
From Stem cell medicine
Cell transplants
8 people, no serious harm
Phase 3
Dopamine cells grown from stem cells and placed in the brain.
Open to join now
-
Early Parkinson's
Prasinezumab antibody (PARAISO)
Locations and eligibility → -
Moderate Parkinson's
Bemdaneprocel cell transplant
Locations and eligibility → -
Early Parkinson's
BHV-8000 pill
Locations and eligibility → -
Parkinson's
Buntanetap pill
Locations and eligibility → -
Parkinson's, UK
Ambroxol (ASPro-PD)
Locations and eligibility → -
Early Parkinson's
NEU-411 for LRRK2-driven disease
Locations and eligibility →
See every recruiting Parkinson's trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
Knowledge on the way
Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.
- AreaQuestionFunded throughNews likely
- Care Does high-intensity exercise slow early Parkinson's? (SPARX3)Northwestern University · NIH Funded through Aug 2026 News likely 2027
- Care Deep brain stimulation tuned to each person's brain circuitsUniversity of Minnesota · NIH Funded through Jul 2027 News likely 2027–2028
- Detection Walking patterns as a digital measure of progressionStanford University · NIH Funded through Jul 2029 News likely 2027–2029
- Causes Why thinking problems differ so much between peopleUniversity of Pennsylvania · NIH Funded through Aug 2029 News likely 2027–2029
- Causes A national Parkinson's research centerEmory University · NIH Funded through Jul 2027 News likely Continuous
What just happened
Tavapadon approved in the US
A once-daily pill, with or without levodopa.
LRRK2-blocking drug did not slow the disease
Stopped in people without the gene variant.
Prasinezumab missed its main goal, phase 3 continues
Secondary analyses suggested an effect in some groups.
Exenatide did not slow Parkinson's
194 people over 96 weeks.
Standard treatment today
- Early symptomsLevodopa, a dopamine agonist or an MAO-B inhibitor, chosen by age and symptoms. Exercise is part of treatment.
- Wearing-off between dosesAdjusting levodopa and adding other medicines, now including tavapadon.
- Advanced, with fluctuationsDeep brain stimulation, continuous infusion pumps or focused ultrasound for selected people.
- Slowing the diseaseNo approved treatment.
How to read this page, and sourcesHow to read this page, and sources
- Symptom treatments and disease-slowing treatments are different goals. Only the first has approved options.
- Early cell-transplant studies are small and have no comparison group.
- Completion dates are what each trial registered. Results usually follow 3 to 12 months later.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Parkinson's trials recruiting now →